MedTrace Logo

Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males

NCT00930215 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-09-10

No results posted yet for this study

Summary

The purpose of the study is to determine whether the HPMC capsule of D961H 40 mg is bioequivalent to gelatine capsules of D961H 40 mg after a steady state is reached on Day 5

Conditions

  • Healthy

Interventions

DRUG

D961H

Oral gelatin capsule

DRUG

D961H

Oral HPMC capsule

Sponsors & Collaborators

Principal Investigators

  • Takenobu Masaoka · AstraZeneca

  • Masataka Date · AstraZeneca KK

  • Shunji Matsuki · Kyushu Clinical Pharmacology Research Clinic

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Completion
2009-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930215 on ClinicalTrials.gov